Short answer: ostarine is the far better-studied of the two. Both came out of the same research program, but only ostarine went through human trials: 3 mg a day for 86 days added 1.3 kg of lean mass and removed 0.6 kg of fat vs placebo, while lowering HDL cholesterol and, in men, total testosterone (Dalton 2011). Andarine (S4) has rat data only, a much shorter half-life in rats, and user reports of vision changes. Users describe andarine as slightly stronger for fat loss; that is anecdotal.

Andarine (S4) Ostarine (MK-2866)
Human trials None published Phase 2 and Phase 3 trials, over 1,000 people
Half-life 2.6–5.3 h in rats; human not established ~14–24 h in humans
Muscle Restored muscle and strength in castrated rats +1.0 to +1.5 kg lean mass in trials
Fat Less body fat in female rats About −0.6 kg vs placebo in 86 days
Testosterone LH and FSH lowered in rats Total testosterone and SHBG down in older men
Vision Yellow tint, night-vision trouble (user reports) Not among the side effects reported in the 86-day trial
Liver Not studied ALT rises in trials; liver-injury case reports

Andarine (S4)

Andarine (S-4, GTx-007) is a nonsteroidal SARM from the same research group and company as ostarine (PubChem). In castrated rats it restored muscle mass, strength and bone with far less effect on the prostate than DHT (Gao 2005), and in female rats it protected bone and reduced body fat (Kearbey 2007). No human trial results have been published. The popular story that it was dropped because a trial found vision problems has no published source we could find; vision changes are a consistent user report. Read more in the Andarine review and S4 before and after.

Ostarine (MK-2866)

Ostarine (enobosarm, GTx-024) is the most studied SARM: trials in older adults, cancer patients and, most recently, older adults losing weight on semaglutide. It is not side-effect free: HDL fell 17–27% and total testosterone fell in older men at 1–3 mg a day (Dalton 2011), and a 2024 breast cancer trial at 9–18 mg a day found serious drug-related side effects (mostly liver enzymes) in 8–16% (Palmieri 2024). It is still not approved anywhere we could find. More: ostarine fact sheet.

Andarine vs Ostarine (Half-life)

Ostarine’s half-life in Phase 1 studies was about 21–24 hours after a single dose and 14–21 hours with daily dosing, so trials used once-daily dosing (EMERALD protocol). Andarine’s half-life was 2.6–5.3 hours in rats (Kearbey 2004); the human value is not established, but users split it into two or three doses. Ostarine is clearly easier to take consistently.

Andarine VS Ostarine – Benefits

Only ostarine has human benefit data. The comparisons below are the original author’s own experience with both, kept as written; they are anecdotal.

Muscle Mass

Both Andarine and Ostarine will preserve muscle during a cut.

The real question is, how much muscle will you gain while on a caloric deficit with these two SARMs?

From the author’s experience: about 2–3 lb of lean mass on a cut with either. For ostarine, the trial figure was about 1.3 kg (2.9 lb) over 86 days at 3 mg a day (Dalton 2011).

Fat Loss

This is where the real battle happens! I found Andarine to be just a tad bit better at fat loss in comparison to Ostarine. The difference is minimal, but it’s still out there and those looking for better results are going to be choosing Andarine for fat loss.

Strength

You will only experience a minor increase in strength while on these two SARMs. Considering the fact that you’ll most likely be taking them on a caloric deficit, you cannot expect to really gain a significant amount of strength.

If I had to compare the two based on the strength gains I’ve made (which were miniscule in their nature), I would have to call it a tie once more.

Andarine VS Ostarine – Side Effects

So far, Andarine might have looked like the better SARM to take, but after this section, things will become unclear as Andarine has a lot of problems when it comes to side effects.

Impaired Vision

While Ostarine doesn’t have this side effect, it is still worthy of mentioning just because Andarine has it and it’s serious.

Users who take higher doses of andarine report a yellow tint and much worse night vision. No study has measured it, so how common it is and whether it always reverses are not established.

I remember driving one night while on an Andarine cycle and I’m being completely honest here – I couldn’t see jack out there! It’s a miracle I came home safely.

Don’t drive if your vision changes.

Suppression

Contrary to popular belief, Andarine and Ostarine do cause suppression to occur in our bodies.

Ostarine lowered total testosterone by about 6–7 nmol/L in older men at 1–3 mg a day, while free testosterone, LH and FSH did not change significantly (Dalton 2011). Andarine lowered LH and FSH in castrated rats (Gao 2005); it has not been measured in people.

The original author judged andarine the more suppressive of the two (anecdotal).

Andarine VS Ostarine – Results

Measured results exist only for ostarine: about +1.3 kg lean mass and −0.6 kg fat vs placebo over 86 days at 3 mg a day, with body weight unchanged. User reports put andarine slightly ahead for fat loss: the original article described a typical ostarine cycle as about 3% body fat and 7 lb lost, and andarine as about 4% and 8–10 lb. Those are rough user estimates at doses far above anything tested. Reader transformations: ostarine before and after and S4 before and after.

Andarine VS Ostarine – Pricing

Per-milligram prices can mislead: andarine is usually taken at higher daily amounts and split through the day, so it often costs more per day than ostarine. Current prices at our partner shop are in the boxes on this page; why we chose it is in the SwissChems review. Quality matters more than price: only 41% of 44 tested SARM products matched their label (Van Wagoner 2017).

Conclusion

Andarine vs ostarine: ostarine has the human evidence (modest lean-mass gains, lower HDL and testosterone, liver-enzyme rises in some), a once-daily half-life and no reported vision problems. Andarine has rat data, a short half-life and consistent user reports of vision changes, and users rate it slightly stronger for fat loss. The original author recommended ostarine for newcomers; the evidence supports that. Compare both with other compounds in the SARMs database.

Frequently asked questions

Is andarine stronger than ostarine?

Unknown; no human andarine dataEvidence: Trial

Users often say andarine is slightly stronger for fat loss, but it has no human study to compare. Ostarine's effects were measured: about 1.3 kg more lean mass and 0.6 kg less fat than placebo over 86 days.

Read the full section

Which is better for cutting, S4 or ostarine?

Only ostarine has trial dataEvidence: Trial

Users report slightly more fat loss on andarine, along with vision changes. Ostarine has trial data, including less lean-mass loss in older adults losing weight on semaglutide (company data).

Read the full section

Does ostarine cause vision problems like andarine?

Not reported in trialsEvidence: User reports

Vision changes were not among the side effects reported in the main 86-day ostarine trial. They are a consistent user report with andarine, mostly at higher doses, and no study has measured them.

Read the full section

Can you stack andarine and ostarine?

Never studiedEvidence: Limited

There is no data on the combination. Both act on the androgen receptor, so suppression would add up.

Which is more suppressive, andarine or ostarine?

UnclearEvidence: Trial

Ostarine lowered total testosterone by about 6–7 nmol/L in older men at 1–3 mg a day. Andarine has not been measured in people; it lowered LH and FSH in rats.

Read the full section

Sources

  1. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial 2011 · PMID 22031847
  2. PubChem: Andarine (CID 9824562), names and synonyms 2026
  3. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats 2005 · PMID 16099859
  4. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats 2007 · PMID 17063395
  5. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial 2024 · PMID 38342115
  6. EMERALD study protocol (ISRCTN12213700, University of Liverpool, version 6.0, 2021): a window of opportunity study of enobosarm in ER+/AR+ early breast cancer 2021
  7. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator 2004 · PMID 15204699
  8. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet 2017 · PMID 29183075